drugset / Trial / NCT06672900
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers
Non-randomizedParallel-groupOpen-labelOther
Summary
This Phase 1 study consists of two parts, all conducted in healthy volunteers (HVs). In Part 1, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Itraconazole; participants will be assigned to receive multiple doses of ALG-000184 and Itraconazole over a two week period. In Part 2, the drug-drug interaction (DDI) potential of ALG-000184 will be explored with Carbamazepine; participants will be assigned to receive multiple doses of ALG-000184 and ascending doses of Carbamazepine over an 18 day period. The 2 parts may be conducted in parallel.
Timeline
- Start
- 2025-01-09
- Primary completion
- 2025-07-07
- Completion
- 2025-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALG-000184 | Other / unclassified | — | — |
| Subject | Carbamazepine | Small molecule | — | — |
| Subject | Itraconazole | Small molecule | — | — |
Indications
No indication recorded.